Citations

Clear

3030 citation(s) found for "Susan, M".

MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in KRAS-mutated advanced pancreatic ductal adenocarcinoma (PDAC).
Mehdi, Maahum , Thalji, Samih Z, Shreenivas, Aditya , Thomas, James P. , Christians, Kathleen K. , Evans, Douglas B. , Hall, William A. , Erickson, Beth , Yazdanpanah, Omid , Aldakkak, Mohammed , Holden, Mary Beth, George, Ben , Oxencis, Carolyn, Chakrabarti, Sakti , Thapa, Bicky , Ahmed, Gulrayz , Kurzrock, Razelle , Tsai, Susan , McFall, Thomas B. , Kamgar, Mandana

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e16260-e16260

10.1200/jco.2022.40.16_suppl.e16260 Get It

e16260 Background: Therapeutic inhibition of constitutive signaling mediated by mutated KRAS in PDAC remains a challenge except for modest success reported with KRAS G12C inhibition. A combinatorial strategy utilizing simultaneous MEK and autophagy inhibition holds therapeutic promise based on mechanism of action and preclinical data. We described characteristics and outcomes of patients (pts) treated with MEK-inh and HCQ at our institution. Methods: Ten KRAS-mutated advanced PDAC pts were treated with trametinib-HCQ (n = 9) or cobimetinib-HCQ (n = 1) off label due to lack of standard treatment options or toxicity concerns with cytotoxic systemic therapy. Trametinib dose was 2 mg once daily orally, Cobimetinib dose was 20 mg BID orally for 3/4 weeks cycles. HCQ was started at 200 mg BID and up-titrated weekly to 600 mg BID. Description of baseline and treatment (tx) characteristics, safety and efficacy is provided. Results: Median age at diagnosis was 61.3 years, and 7 pts were female. The number of prior lines of tx were 0/1/2/3/4 in 3/2/1/2/2 pts, respectively. KRAS mutations were: G12R/G12D/G12V/Q61H in 6/2/1/1 pts. Median overall survival was 6.6 months (m) in all pts, and 6.6/1.7 m in KRAS G12R/other KRAS (p = 0.31). Median progression-free survival was 5.7/6.2/1.5 m in all/ KRAS G12R/other KRAS (p = 0.16). Among 8 pts with evaluable response, 1 (12%) had partial response ( KRAS G12R) and 4 (50%) stable disease (3/4 KRAS G12R) as best response with disease control rate of 63%/80%/33% in total/ KRAS G12R/other KRAS (p = 0.29). Toxicity data are summarized in table 1. Conclusions: MEK-inh-HCQ demonstrated modest efficacy and manageable toxicities among KRAS G12R PDAC pts. Unlike G12D and G12V mutations in the KRAS gene, G12R is defective of conductive interactions for both PI3Ka and NF1. This ultimately results in a weakened signal being shunted through MAPK cascade and provides a unique opportunity where MEK inh can ablate signaling without the alternate pathways and WT-RAS isoforms compensating. Furthermore, as activation of PI3Ka is known to suppress autophagy, its lack of activation by KRAS G12R further sensitizes cells to HCQ. The combination therapy MEK-inh-HCQ is therefore mechanistically-rationale and warrants the further investigation of KRAS G12R as an actionable biomarker.[Table: see text]
Phase I/II trial of BMS-986205 and nivolumab as first line therapy in hepatocellular carcinoma.
Huynh, Jasmine , Cho, May Thet, Tam, Kit , Singh, Amisha , Naderi, Sima, Lamba, Ramit, McGahan, John P. , Loehfelm, Thomas W. , Navarro, Shannon M. , Lara, Frances, Martinez, Anthony, Garcia, Leslie, Kim, Edward , Cho, May , Monjazeb, Arta Monir , Fananapazir, Ghaneh , STEWART, SUSAN LEROY , Martinez, Anthony

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e16200-e16200

10.1200/jco.2022.40.16_suppl.e16200 Get It

e16200 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme expressed by HCC which helps to orchestrate immune suppression within the tumor microenvironment (TME) and may contribute to primary and acquired resistance of PD-(L)1 inhibitors. BMS-986205 is a novel oral drug that potently and selectively inhibits IDO1. This Phase I/II study is evaluating the safety and tolerability of the combination of BMS-986205 and nivolumab as first-line therapy in HCC. Methods: Patients (pts) ≥18y with untreated, unresectable/metastatic HCC received BMS-986205 in combination with nivolumab. A fixed dose of Nivolumab 240mg/m2 IV was administered on Day 1 of each 14-day cycle. BMS-986205 was an oral tablet administered daily; a total of two dose levels (50-100mg) were given to determine dose limiting toxicities (DLT) during the dose-escalation Phase I of the study. Safety was assessed using CTCAE v5.0 criteria, and efficacy was assessed by objective response rate (ORR) using RECIST v1.1 criteria. Secondary objectives included preliminary data on disease control rate (DCR), duration of response (DOR), ORR using immune RECIST criteria (iRECIST), progression free survival (PFS) and overall survival (OS). Results: Here we report the results of the dose escalation cohort. Eight pts were treated with median age 69y [60-76]; 75% male; and PS 0 (3 pts) or 1 (5 pts). Pts were White (62.5%), Asian (25%), and African American (12.5%). Six of 8 pts had underlying viral hepatitis (5 hepatitis C, 1 hepatitis B), and all pts were Child Pugh A at enrollment with median baseline alpha-fetoprotein (AFP) level 41.8 [3.8–917.2]; 4 pts received prior local therapies. A total of 91 cycles of therapy were administered; 2 pts received 27 and 43 cycles of treatment each. Six pts were evaluable for DLT; 2 pts were replaced for DLT assessment due to insufficient dose administered, unrelated to toxicity. No DLTs were observed at either the 50 or 100mg dose of BMS-986205. There were 24 treatment-related adverse events (TRAEs), 4 of which were Grade 3 events; there were no Grade 4-5 events. The most common TRAEs of all grades were AST elevation and ALT elevation in 3 pts, and diarrhea, maculopapular rash and increased alkaline phosphatase in 2 pts each. Grade 3 events were diarrhea and AST elevation (1 pt), and hyperglycemia and pancreatitis requiring treatment discontinuation (1 pt). Eight pts were evaluable for efficacy with best response of partial response in 1 pt (12.5%) and stable disease in 3 pts (37.5%), yielding a DCR of 50%. Median PFS was 8.5 weeks; median OS has not been reached. Conclusions: Combination BMS-986205 and nivolumab showed a manageable safety profile with durable benefit as 1st line therapy in a meaningful subset of patients with unresectable/metastatic HCC. Clinical trial information: NCT03695250.
Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.
Sethunath, Vidyalakshmi , Ameye, Lieveke , Paesmans, Marianne , El-Abed, Sarra , Choudhury, Anup , Napoleone, Sylvia, Chumsri, Saranya , Piccart, Martine , Moreno‐Aspitia, Alvaro , Viale, Giuseppe , Rimawi, Mothaffar F. , Osborne, C. Kent, Rimawi, Mothaffar , El-Abed, Sarra , Angelis, Carmine De , Veeraraghavan, Jamunarani , Gómez, Henry , Hilsenbeck, Susan Galloway , Azambuja, Evandro de , Schiff, Rachel

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 522-522

10.1200/jco.2022.40.16_suppl.522 Get It

522 Background: Our preclinical findings suggest a role for the mevalonate pathway (MVA) in treatment resistance in HER2+ BC by providing alternative growth and survival signaling to bypass potent HER2 blockade, which could be overcome by the MVA inhibitors statins and nitrogen-containing bisphosphonates (NBs). Here we explored the effect of MVA inhibitors’ use on pts’ outcomes in the ALTTO trial (BIG2-06; NCT00490139). Methods: In the ALTTO trial, 8381 pts with HER2+ BC were randomized to 1 year of adjuvant lapatinib (L), trastuzumab (T), L+T, or T→L. All pts with documented treatment start with statins or NBs < 1 year after randomization were considered as MVA inhibitors users. Survival curves, with a median follow-up of 6.9 years, for disease-free survival (DFS), distant relapse-free interval (DRFI), BC-specific survival (BCSS), and overall survival (OS) according to MVA inhibitors use were estimated by the Kaplan Meier method and Log-rank test. All multivariate survival analyses employed a Cox proportional hazards regression model, adjusting for tumor size, nodal status, hormonal receptor (HoR), menopausal status, BMI, timing of chemo, and randomization arm. We considered interactions terms in Cox’s model between MVA inhibitors use and randomization arm, hormonal status, and BMI group. Results: Among the 8381 pts included in this study, 493 and 299 were statins or NBs users, respectively. Table 1 summarizes the significant differences in pts’ characteristics according to MVA inhibitors use ( P <.005). In multivariate survival analyses, only NBs use was associated independently with better BCSS (HR, 0.44; 95% CI, 0.23 - 0.84; P = 0.014). Statin use was not independently associated with prognosis but only in interaction with pts characteristics: worse DFS, BCSS and OS in pts treated with L+T, worse DRFI and OS in pts treated with HoR+ BC (respective interaction P-values <0.05 in the Cox’s model). Conclusions: NBs independently predicted improved BC-specific outcome in pts with HER2+ BC treated with adjuvant anti-HER2 therapy. Statin use was associated with an inferior outcome in pts with HoR+ disease and/or those treated with L+T. Whether this inferior association in statin users may reflect the underlying predisposition factors that can weaken the efficacy of anti-HER2 treatments and whether this effect was observed only in the L+T arm due to the more potent inhibition of the HER2 signaling pathway remain open questions. Further clinical investigations on the impact of MVA inhibitors on the outcome of pts with HER2+ BC are warranted. [Table: see text]
The aryl hydrocarbon receptor instructs the immunomodulatory profile of a subset of Clec4a4 + eosinophils unique to the small intestine
Wang, Wei-Le , Kasamatsu, Jun , Gilfillan, Susan , Luccia, Blanda Di , Panda, Santosh K., Kim, DoHyun , Desai, Pritesh , Bando, Jennifer K. , Yomogida, Kentaro , Hoshino, Hitomi , Fukushima, Mana, Jacobsen, Elizabeth A. , Dyken, Steven J. Van , Ruedl, Christiane , Gilfillan, Susan , Bando, Jennifer K , Van Dyken, Steven J , Ruedl, Christiane , Colonna, Marco , Jacobsen, Elizabeth A , Joshita, Satoru , Panda, Santosh K., Huang, Stanley Ching‐Cheng , Cella, Marina , Colonna, Marco

Mayo Clinic

Proceedings of the National Academy of Sciences | June 2, 2022 | Volume: 119 | Issue: 23 | Pages: No page available

10.1073/pnas.2204557119 | PMID 35653568 Get It

Significance Eosinophils contribute to type 2 immunity against helminths and allergens. The small intestine harbors eosinophils with incompletely understood pathophysiological roles. Here, we show that intestinal eosinophils include two subsets. One expresses the inhibitory receptor Clec4a4 and the inhibitory ligand PD-L1 and is unique to the small intestine; the other manifests a proinflammatory phenotype. Both subsets are blood derived. Remarkably, Clec4a4 + eosinophils were instructed by the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor that imprints many gut immune cells. Selective AHR deletion in eosinophils depleted Clec4a4 + eosinophils, augmented innate lymphocytes producing type 2 cytokines, and enhanced helminth clearance. We conclude that Clec4a4 + eosinophils have immunomodulatory functions, which could be harnessed for the therapy of food allergies and eosinophilic gastrointestinal disorders.
Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder
Gardea-Resendez, Manuel, Taylor-Desir, Monica J., Romo-Nava, Francisco, Bond, David, Vallender, Eric J., Cuellar-Barboza, Alfredo B., Prieto, Miguel L., Nunez, Nicolas, Veldic, Marin, Ozerdem, Aysegul, Singh, Balwinder, Markota, Matej, Colby, Colin L., Coombes, Brandon J., Biernacka, Joanna M., McElroy, Susan L., Frye, Mark A., Singh, Balwinder , Bond, David J. , Özerdem, Ayşegül , Romo‐Nava, Francisco , Gardea‐Resendez, Manuel , Romo-Nava, F , Bond, David J , Singh, Balwinder , Ozerdem, Aysegul , Gardea-Resendez, Manuel , Taylor-Desir, Monica J., Vallender, Eric J., Cuellar-Barboza, Alfredo B., Prieto, Miguel L., Nunez, Nicolas, Veldic, Marin, Singh, Balwinder, Markota, Matej, Colby, Colin L., Coombes, Brandon J., Biernacka, Joanna M., McElroy, Susan L., Frye, Mark A.

Mayo Clinic

Journal of Clinical Psychopharmacology | May 31, 2022 | Volume: 42 | Issue: 2 | Pages: 159-162

10.1097/jcp.0000000000001532 | PMID 35230047 Get It

Abstract Purpose Recognizing the negative impact that antipsychotic-induced movement disorders have on the quality of life and treatment outcomes in bipolar disorder (BD), this study aimed to assess clinical correlates and antipsychotic use patterns of tardive dyskinesia (TD+) in BD. Materials and Methods Participants with and without TD were included. Clinical variables were compared using t-test and χ2 test. Antipsychotic use patterns in TD+, including number of trials, mean doses, and estimated cumulative exposure, were assessed in a case-only analysis. Results The prevalence rate of TD was 5.1%. In comparison to the TD− group (n = 1074), TD+ participants (n = 58) were older, more likely to be female and have type I bipolar illness. There were 60.3% of the TD+ group that continued using antipsychotics at study entry and had a mean cumulative exposure to antipsychotics of 18.2 ± 15.6 years. Average dose, in haloperidol equivalents, was 5.9 ± 3.5 mg and 77.7% of the trials were second-generation antipsychotics. Conclusions This study confirms previously identified TD risk factors, such as age, sex, and bipolar subtype in a large BD cohort. Limitations included a cross-sectional design and the lack of tardive illness severity assessment. As atypical antipsychotics continue to be primary mood stabilization treatment, attempting to harmonize large data sets to identify additional biomarkers of tardive risk will optimize individualized care for patients with BD.
Development and Early Experience of a Primary Care Learning Collaborative in a Large Health Care System
Erickson, Rodney A. , Chavez, Augustine , Cristiani, Valeria, DeJesus, Ramona S. , Laabs, Susan, Presutti, R. John , Rosas, Steven , Westfall, Erin , Witt, Terrence J. , Erickson, Rodney , Chavez, Augustine S , DeJesus, R S , Presutti, Richard J , Rosas, Steven L , Westfall, Erin , Witt, Terrence , Thacher, Thomas D , Dabrh, Abd Moain Abu , Thacher, Tom D.

Mayo Clinic

Journal of Primary Care & Community Health | May 21, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221089775 | PMID 35603490 Get It

Introduction: Primary care clinicians are presented with hundreds of new clinical recommendations and guidelines. To consider practice change clinicians must identify relevant information and develop a contextual framework. Too much attention to information irrelevant to one’s practice results in wasted resources. Too little results in care gaps. A small group of primary care clinicians in a large health system sought to address the problem of vetting new information and providing peer reviewed context. This was done by engaging colleagues across the system though a primary care learning collaborative. Methods: The collaborative was a grass roots initiative between community and academic-based clinicians. They invited all the system’s primary care clinicians to participate. They selected new recommendations or guidelines and used surveys as the principal communication instrument. Surveys shared practice experience and also invited members to give narrative feedback regarding their acceptance of variation in care relate to the topic. A description of the collaborative along with its development, processes, and evolution are discussed. Process changes to address needs during the COVID-19 pandemic including expanded information sharing was necessary. Results: Collaborative membership reached across 5 states and included family medicine, internal medicine, and pediatrics. Members found involvement with the collaborative useful. Less variation in care was thought important for public health crises: the COVID pandemic and opioid epidemic. Greater practice variation was thought acceptable for adherence to multispecialty guidelines, such as diabetes, lipid management, and adult ADHD care. Process changes during the pandemic resulted in more communications between members to avoid practice gaps. Conclusion: An internet-based learning collaborative in a health system had good engagement from its members. Using novel methods, it was able to provide members with feedback related to the importance of new practice recommendations as perceived by their peers. Greater standardization was thought necessary when adopting measures to address public health crisis, and less necessary when addressing multispecialty guidelines. By employing a learning collaborative, this group was able to keep members interested and engaged. During the first year of the COVID pandemic the collaborative also served as a vehicle to share timely information.
Infected Intrathecal Pump Exchange with Preservation of Original Catheter in a Cancer Patient
Joseph, Amira , Bendel, Markus A. , Moeschler, Susan M. , Bendel, Markus, Moeschler, Susan

Mayo Clinic

Pain Medicine | May 20, 2022 | Volume: 23 | Issue: 11 | Pages: 1915-1920

10.1093/pm/pnac078 | PMID 35595252 Get It

Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Zhu, Mojun , Foster, Nathan R. , Hartley, Christopher , Mounajjed, Taofic, Fruth, Briant, Beamer, Staci E. , Harrington, Susan M. , Pitot, Henry C., Sanhueza, Cristobal T., Feng, Yening , Herrmann, Joerg , Huang, Bing, Bekaii‐Saab, Tanios , Wigle, Dennis A. , Ahn, Daniel H. , Hallemeier, Chris L., Yoon, Harry H. , Salomao, Marcela A, Fruth, Briant F, Feng, Yening , McWilliams, Robert R , Huang, Bing Q, Ma, Wen Wee , Dong, Haidong , Wigle, Dennis, Blackmon, Shanda , Yoon, Harry H , Bekaii-Saab, Tanios S , Chen, Chunhua , Hartley, Christopher P , Salomao, Marcela , Kim, Yohan , McWilliams, Robert R. , Lucien, Fabrice , Wee, Wen , Dong, Haidong

Mayo Clinic

Clinical Cancer Research | May 12, 2022 | Volume: 28 | Issue: 14 | Pages: 3021-3031

10.1158/1078-0432.ccr-22-0413 | PMID 35552651 Get It

Abstract Purpose: This phase Ib/2 trial investigated pembrolizumab-containing trimodality therapy in patients with gastroesophageal junction (GEJ) adenocarcinoma. Patients and Methods: Patients with GEJ adenocarcinoma (cT1–3NanyM0) received neoadjuvant pembrolizumab-containing chemoradiation (CROSS regimen) followed by surgical resection and adjuvant pembrolizumab. The primary endpoints were tolerability in the first 16 patients and pathologic complete response [pCR (ypT0N0)]. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). An independent propensity-score-matched cohort (treated with CROSS without immunotherapy) was used for comparison. Exploratory analyses included immune biomarkers in the tumor microenvironment (TME) and plasma. Results: We enrolled 31 eligible patients, of whom 29 received all expected doses of neoadjuvant pembrolizumab and 28 underwent R0 resection. Safety endpoints were met. The primary efficacy endpoint was not met [7/31 (22.6%) achieved pCR]. Patients with high [i.e., combined positive score (CPS) ≥ 10] baseline expression of programmed death (PD)-L1 in the TME had a significantly higher pCR rate than those with low expression [50.0% (4/8) vs. 13.6% (3/22); P = 0.046]. Patients with high PD-L1 expression also experienced longer PFS and OS than propensity-score-matched patients. Among trial patients with PD-L1 CPS &lt; 10, unprespecified analysis explored whether extracellular vesicles (EV) could identify further responders: an elevated plasma level of PD-L1–expressing EVs was significantly associated with higher pCR. Conclusions: Adding pembrolizumab to trimodality therapy showed acceptable tolerability but did not meet the pre-specified pCR endpoint. Exploratory analyses suggested that high PD-L1 expression in the TME and/or on EVs may identify patients most likely to achieve tumor response.
Heterozygous variants in PRPF8 are associated with neurodevelopmental disorders
O’Grady, Lauren , Vergano, Samantha A. Schrier , Hoffman, Trevor L. , Sarco, Dean, Cherny, Sara , Bryant, Emily , Schultz‐Rogers, Laura , Sacharow, Stephanie , Immken, LaDonna, Holder, Susan, Blackwell, Rebecca R., Buchanan, Catherine A., Yusupov, Roman, Lecoquierre, François , Guerrot, Anne‐Marie , Rodan, Lance H. , Vries, Bert B.A. de , Kamsteeg, Erik Jan, Palomares‐Bralo, María , Brown, Natasha J. , Klee, Eric W. , Babovic‐Vuksanovic, Dusica , Rhodes, Lindsay, Person, Richard, Begtrup, Amber, Keller‐Ramey, Jennifer, Santiago‐Sim, Teresa, Schnur, Rhonda E. , Gold, Nina B. , Schrier Vergano, Samantha , Lecoquierre, Francois , Rodan, Lance , de Vries, Bert B A , Santos Simarro, Fernando , Palomares-Bralo, Maria , Babovic-Vuksanovic, Dusica, Sweetser, David A , Chung, Wendy K. , Pais, Lynn , Ferrer, Alejandro , Begtrup, Amber Hogart

Mayo Clinic

American Journal of Medical Genetics Part A | May 11, 2022 | Volume: 188 | Issue: 9 | Pages: 2750-2759

10.1002/ajmg.a.62772 | PMID 35543142 Get It

Abstract The pre‐mRNA‐processing factor 8, encoded by PRPF8, is a scaffolding component of a spliceosome complex involved in the removal of introns from mRNA precursors. Previously, heterozygous pathogenic variants in PRPF8 have been associated with autosomal dominant retinitis pigmentosa. More recently, PRPF8 was suggested as a candidate gene for autism spectrum disorder due to the enrichment of sequence variants in this gene in individuals with neurodevelopmental disorders. We report 14 individuals with various forms of neurodevelopmental conditions, found to have heterozygous, predominantly de novo, missense, and loss‐of‐function variants in PRPF8 . These individuals have clinical features that may represent a new neurodevelopmental syndrome.
Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes
Baidal, David A. , Warnock, Megan, Geyer, Susan, Marks, Jennifer B. , Moran, Antoinette , Sosenko, Jay M. , Xu, Ping , Evans‐Molina, Carmella

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | May 7, 2022 | Volume: 107 | Issue: 8 | Pages: e3273-e3280

10.1210/clinem/dgac285 | PMID 35524749 Get It

Abstract Context Decreased first-phase insulin response (FPIR) during intravenous glucose tolerance testing (IVGTT) is an early indicator of β-cell dysfunction and predictor of type 1 diabetes (T1D). Objective Assess whether oral glucose tolerance test (OGTT) measures could serve as FPIR alternatives in their ability to predict T1D in autoantibody positive (Aab+) subjects. Design OGTT and IVGTT were performed within 30 days of each other. Eleven OGTT variables were evaluated for (1) correlation with FPIR and (2) T1D prediction. Setting Type 1 Diabetes TrialNet “Oral Insulin for Prevention of Diabetes in Relatives at Risk for T1D” (TN-07) and Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) studies clinical sites. Patients TN-07 (n = 292; age 9.4 ± 6.1 years) and DPT-1 (n = 194; age 15.1 ± 10.0 years) Aab + relatives of T1D individuals. Main outcome measures (1) Correlation coefficients of OGTT measures with FPIR and (2) T1D prediction at 2 years using area under receiver operating characteristic (ROCAUC) curves. Results Index60 showed the strongest correlation in DPT-1 (r = -0.562) but was weaker in TN-07 (r = -0.378). C-peptide index consistently showed good correlation with FPIR across studies (TN-07, r = 0.583; DPT-1, r = 0.544; P &lt; 0.0001). Index60 and C-peptide index had the highest ROCAUCs for T1D prediction (0.778 vs 0.717 in TN-07 and 0.763 vs 0.721 in DPT-1, respectively; P = NS), followed by FPIR (0.707 in TN-07; 0.628 in DPT-1). Conclusions C-peptide index was the strongest measure to correlate with FPIR in both studies. Index60 and C-peptide index had the highest predictive accuracy for T1D and were comparable. OGTTs could be considered instead of IVGTTs for subject stratification in T1D prevention trials.